1,766,889 research outputs found
Resolución UNRN N° 531/2009. Designar docente interino.
Fil: Universidad Nacional de Río Negro (U). Universidad Nacional de Río Negro. Río Negro, ArgentinaResolución UNRN N° 531/2009. Designar docente interino.fals
Philosophy [531]
Philosophy.
This manuscript is now IO Islamic B160C in the India Office collections.
[metadata: Otto Loth, A Catalogue of the Arabic Manuscripts in the Library of the India Office, (volume 1), no. 531 here with further notations and hyperlinks].
531.
B160C. Size 83/4 in. by 5 in.; foll.8. From nineteen to twenty-nine lines in a page.
حاشيه ملا مرزاجان بر تصديقات مطالع
The commencement of Glosses on the second part of Ḳuṭb al-dîn’s Commentary on the مطالع الانوار , ascribed to MÎRZÂ JÂN (d. A.H. 994).1
Begins:(قوله) اى المجهولات التصديقية فسر التصديقات بالمجهولات التصديقية.
This MS. ends with fol. 8r.; the back of this fol. is left blank and marked with بياض صحيح ; the remainder, however, is missing. Written in Nasta’lîḳ of varying size. Additional notes by the author on the margin.
Cat. 237, xiv.
1 Cf. no.529
Going Beyond Counting First Authors in Author Co-citation Analysis
The present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Band 6, 531 (Sammlung Friedlaender)
BAND 6, 531 (SAMMLUNG FRIEDLAENDER)
Band 6, 531 (Sammlung Friedlaender) (Public Domain) (1
Band 5, 531 (Sammlung Friedlaender)
BAND 5, 531 (SAMMLUNG FRIEDLAENDER)
Band 5, 531 (Sammlung Friedlaender) (Public Domain) (1
Band 2, 531 (Sammlung Friedlaender)
BAND 2, 531 (SAMMLUNG FRIEDLAENDER)
Band 2, 531 (Sammlung Friedlaender) (Public Domain) (1
Resolución CSDEyVE Nº 28/2020. Aprobar el Reglamento de Circulación y Préstamos Bibliográficos de la Universidad Nacional de Río Negro. Derogar Resolución UNRN Nº 531/2011.
Fil: Consejo Superior de Docencia, Extensión y Vida Estudiantil (D). Universidad Nacional de Río Negro. Río Negro, ArgentinaResolución CSDEyVE Nº 28/2020. Aprobar el Reglamento de Circulación y Préstamos Bibliográficos de la Universidad Nacional de Río Negro. Derogar Resolución UNRN Nº 531/2011.tru
Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531
Breast cancer is the most common type of cancer in women and notwithstanding important therapeutic advances, remains the second leading cause of cancer-related death. Despite extensive research relating to the hormone ghrelin, responsible for the stimulation of growth hormone release and appetite, little is known of the effects of its unacylated form, especially in cancer. The present study aimed to characterize effects of unacylated ghrelin on breast cancer cells, define its mechanism of action, and explore the therapeutic potential of unacylated ghrelin or analog AZP-531. We report potent anti-tumor effects of unacylated ghrelin, dependent on cells being cultured in 3D in a biologically-relevant extracellular matrix. The mechanism of unacylated ghrelin-mediated growth inhibition involves activation of Gαi and suppression of MAPK signaling. AZP-531 also suppresses the growth of breast cancer cells in vitro and in xenografts, and may be a novel approach for the safe and effective treatment of breast cancer
- …
